Chrysophanol Attenuates Airway Inflammation and Remodeling Through Nuclear Factor-Kappa B Signaling Pathway in Asthma

Guihua Song,Yan Zhang,Suping Yu,Weigang Lv,Zhiwei Guan,Mengmeng Sun,Jing Wang
DOI: https://doi.org/10.1002/ptr.6444
2019-01-01
Abstract:Chrysophanol (CHR), a purified active constituent extracted from Rheum palmatum L., possesses anti‐inflammatory activity. This study aimed to evaluate its effects on asthma‐associated airway inflammation and remodeling. BALB/c mice were sensitized and challenged by ovalbumin (OVA) and administrated with different doses of CHR. We found that CHR decreased OVA‐induced pulmonary inflammation: the levels of interleukin (IL)‐4, IL‐5, and IL‐13, tumor necrosis factor (TNF)‐α, and inducible nitric oxide synthase were downregulated. CHR also attenuated airway remodeling induced by OVA challenge—CHR inhibited pulmonary α‐smooth muscle actin expression. Moreover, both the nuclear translocation and activity of NF‐κB p65 were inhibited by CHR in the asthmatic lung. Enhanced autophagy was initiated in the lung by OVA challenge as evidenced by upregulated light chain 3 beta, autophagy‐related protein 5, and Beclin 1. CHR suppressed OVA‐induced alterations in these autophagy‐related molecules. In vitro, CHR (2 or 20 μM) was used to treat human pulmonary epithelial BEAS‐2B cells in the presence of 10 ng/ml recombinant TNF‐α. CHR not only exhibited the antiproliferation effect but also inhibited the activation of nuclear factor‐kappa B (NF‐kB) signaling pathway in TNF‐α‐treated BEAS‐2B cells. In conclusion, our study indicates that CHR has the potential to ameliorate asthma.
What problem does this paper attempt to address?